Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients.

Content Provider	Semantic Scholar
Author	Dai, Zhiming Zhang, Wanggang Cao, Xing-Mei Zhang, Yang Dai, Zhijun
Copyright Year	2016
Abstract	The optimal conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute leukemia remains undefined. We evaluated the outcomes in 30 patients with acute leukemia who underwent allo-HSCT from human leukocyte antigen-matched donors after conditioning with busulfan and fludarabine (BuFlu). The regimen comprised injection of busulfan 3.2 mg/kg daily on 4 consecutive days and fludarabine 30 mg/m2 daily for 4 doses. All 30 patients achieved hematopoiesis reconstitution with full donor chimerism confirmed by short tandem repeat DNA analysis. The most common regimen-related toxicity was mucositis (86.7%), followed by cytomegalovirus infection (80%). Serious regimen-related toxicities were rare. Acute graft vs. host disease (aGVHD) was detected in 46.7% of the patients; 33.4% had grade I-II aGVHD and 13.3% had grade III-IV aGVHD. Chronic GVHD (cGVHD) was noted in 20% of the patients. The overall survival and disease-free survival rates were 66.7 and 53%, respectively, with a median follow-up of 25 months for surviving patients. Therefore, BuFlu was an effective conditioning regimen with a low rate of transplant-related adverse effects and increased antileukemic effects in patients with acute leukemia undergoing allo-HSCT.
Starting Page	667
Ending Page	671
Page Count	5
File Format	PDF HTM / HTML
DOI	10.3892/mco.2016.765
PubMed reference number	27073687
Journal	Medline
Volume Number	4
Issue Number	4
Alternate Webpage(s)	https://www.spandidos-publications.com/10.3892/mco.2016.765/download
Alternate Webpage(s)	https://doi.org/10.3892/mco.2016.765
Journal	Molecular and clinical oncology
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article